FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014032351910/30/14 new patent  Heterocyclic compounds as b-raf inhibitors for treatment of cancer
42014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
52014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
62014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
72014027501709/18/14Cgrp receptor antagonists
82014025681809/11/14Nano-suspension process
92014024428908/28/14Cold storage system for storing pharmaceutical product containers
102014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
112014023430108/21/14Modulation of pilr to treat immune disorders
122014023553708/21/14N-glycosylated insulin analogues
132014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
142014022722308/14/14Pegylated interleukin-10
152014022725008/14/14Stable formulations of antibodies to tslp
162014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
172014022729208/14/14Anti-mcam antibodies and associated methods of use
182014022002708/07/141d05 pcsk9 antagonists
192014022138308/07/14Cetp inhibitors
202014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
212014020656307/24/14Biomarkers for psoriasis
222014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
232014020664107/24/14Remedy
242014020666507/24/14Selective glycosidase inhibitors and uses thereof
252014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
262014020671507/24/14Preparation and use of compounds as protease inhibitors
272014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
282014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
292014017015406/19/14Engineered anti-il-23r antibodies
302014017065806/19/14Mammalian cytokines; related reagents
312014017143706/19/14Oxazole derivatives useful as inhibitors of faah
322014017145606/19/14Fused tricyclic compounds as mtor inhibitors
332014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
342014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
352014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
362014014744205/29/14Use of il-23 antagonists for treatment of infection
372014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
382014014095405/22/14Methods of modulating cytokine activity; related reagents
392014014101205/22/14Engineered anti-tslp antibody
402014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
412014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
422014014211505/22/14Inhibitors of the renal outer medullary potassium channel
432014014095405/22/14Methods of modulating cytokine activity; related reagents
442014014101205/22/14Engineered anti-tslp antibody
452014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
462014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
472014014211505/22/14Inhibitors of the renal outer medullary potassium channel
482014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
492014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
502014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
512014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
522014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
532014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
542014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
552014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
562014011291904/24/14Interleukin-10 antibodies
572014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
582014011291904/24/14Interleukin-10 antibodies
592014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
602014010588704/17/14Methods for modulating il-33 activity
612014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
622014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
632014010588704/17/14Methods for modulating il-33 activity
642014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
652014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
662014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
672014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
682014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
692014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
702014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
712014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
722014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
732014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
742014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
752014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
762014004574602/13/14Antidiabetic tricyclic compounds
772014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
782014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
792014003762702/06/14Modulation of pilr receptors to treat microbial infections
802014003894202/06/14Rorgammat inhibitors
812014003897002/06/14Bridged and fused antidiabetic compounds
822014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
832014003076001/30/14Pavec
842014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
852014003134901/30/14Inhibitors of the renal outer medullary potassium channel
862014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
872014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
882013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
892013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
902013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
912013032323912/05/13Modulation of pilr receptors to treat sepsis
922013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
932013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
942013032448312/05/13Mammalian cell surface antigens; related reagents
952013032461012/05/13Cathepsin cysteine protease inhibitors
962013032472812/05/13Process for the preparation of an orexin receptor antagonist
972013031635411/28/13Mammalian cytokine; related reagents
982013029627811/07/13Diazeniumdiolate derivatives
992013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1002013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1012013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1022013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1032013025167709/26/13Genetic markers associated with interferon-alpha response
1042013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1052013023751809/12/13Novel compounds that are erk inhibitors
1062013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1072013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1082013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1092013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1102013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1112013021657508/22/13Recombinant subunit dengue virus vaccine
1122013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1132013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1142013021776608/22/13Formulations for cathepsin k inhibitors
1152013021657508/22/13Recombinant subunit dengue virus vaccine
1162013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1172013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1182013021776608/22/13Formulations for cathepsin k inhibitors
1192013020306008/08/13Mammalian genes; related reagents
1202013020306008/08/13Mammalian genes; related reagents
1212013018927807/25/13Antagonists of pcsk9
1222013018927807/25/13Antagonists of pcsk9
1232013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1242013015672906/20/13Mammalian receptor proteins; related reagents and methods
1252013015677106/20/13Fdf03 antibodies and uses thereof
1262013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1272013015672906/20/13Mammalian receptor proteins; related reagents and methods
1282013015677106/20/13Fdf03 antibodies and uses thereof
1292013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1302013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1312013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1322013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1332013013104105/23/13Spirocyclic compounds
1342013013104205/23/13Spiroxazolidinone compounds
1352013013104105/23/13Spirocyclic compounds
1362013013104205/23/13Spiroxazolidinone compounds
1372013012200905/16/13Engineered anti-il-23p19 antibodies
1382013012320005/16/13Mammalian cell surface antigens; related reagents
1392013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1402013012200905/16/13Engineered anti-il-23p19 antibodies
1412013012320005/16/13Mammalian cell surface antigens; related reagents
1422013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1432013011522305/09/13Antagonists of pcsk9
1442013011623105/09/13Tyrosine kinase inhibitors
1452013011522305/09/13Antagonists of pcsk9
1462013011623105/09/13Tyrosine kinase inhibitors
1472013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1482013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1492013007139003/21/13Method for preparing antibodies having improved properties
1502013006481703/14/13Engineered anti-il-23r antibodies
1512013005985003/07/13Aza-indole derivatives useful as modulators of faah
1522013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1532013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1542013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1552013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1562013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1572013003531202/07/13Cathepsin cysteine protease inhibiors
1582013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1592013001804801/17/13Oxazole derivatives useful as modulators of faah
1602013001252601/10/13Oxazole derivatives useful as modulators of faah
1612013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1622013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1632012032967912/27/12Eukaryotic cell display systems
1642012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1652012031620012/13/12Pyridone derivatives
1662012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1672012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1682012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1692012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1702012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1712012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1722012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1732012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1742012019690108/02/12Tertiary amide orexin receptor antagonists
1752012019070107/26/12Renin inhibitors
1762012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1772012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1782012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1792012016415806/28/12Anti-addl monoclonal antibody and use thereof
1802012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1812012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1822012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1832012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1842012014275206/07/12Hiv protease inhibitors
1852012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1862012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1872012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1882012012150805/17/12Radiolabeled cgrp antagonists
1892012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1902012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1912012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1922012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1932012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1942012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1952012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1962012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1972012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1982012008348304/05/12Inhibitors of hepatitis c virus replication
1992012008267904/05/12Antagonists of pcsk9
2002012008268004/05/12Antagonists of pcsk9
2012012007679903/29/12Antagonists of pcsk9
2022012007796403/29/12Antagonists of pcsk9
2032012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2042012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2052012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2062012003521402/09/12Renin inhibitors
2072012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2082012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2092012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2102012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2112012002107401/26/12P2x3, receptor antagonists for treatment of pain
2122012002194801/26/12Surface display of whole antibodies in eukaryotes
2132012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2142012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2152012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2162012000958001/12/12Methods for quantitating small rna molecules
2172012001019301/12/12Cgrp receptor antagonists
2182012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2192012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2202012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2212012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2222011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2232011030107912/08/11Neuromedin u receptor agonists and uses thereof
2242011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2252011029473512/01/11Mechanism of neuromedin u action and uses thereof
2262011029477712/01/11Beta-lactamase inhibitors
2272011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2282011025059110/13/11Method of designing sirnas for gene silencing
2292011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2302011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2312011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2322011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2332011023049809/22/11Biaryl carboxamides
2342011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2352011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2362011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2372011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2382011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2392011021820209/08/11Soluble guanylate cyclase activators
2402011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2412011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2422011020162108/18/11Angiotensin ii receptor antagonists
2432011019595708/11/11Substituted diazepan orexin receptor antagonists
2442011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2452011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2462011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2472011017811707/21/11Oxazolobenzimidazole derivatives
2482011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2492011017220507/14/11Monocyclic amide cgrp receptor antagonists


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo